| 2011 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer
| INVESTIGATIONAL NEW DRUGS |
| 2012 | Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2009 | Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma | ONCOLOGY |
| 2015 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |
| 1999 | Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small cell lung cancer | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2009 | Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2012 | Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
| CANCER |
| 2016 | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer | GASTRIC CANCER |
| 2022 | Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
| JOURNAL OF HEMATOLOGY & ONCOLOGY |
| 2013 | Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
| GUT AND LIVER |
| 2013 | Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
| ANNALS OF ONCOLOGY |
| 2007 | Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
| CANCER |
| 2008 | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. | ANTI-CANCER DRUGS |
| 2019 | Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer | RADIOTHERAPY AND ONCOLOGY |
| 2012 | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | ANNALS OF HEMATOLOGY |
| 2009 | Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2011 | Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2017 | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer | EUROPEAN JOURNAL OF CANCER |
